drugset / Trial / NCT00464958
One Year Extension Study To Protocol C2/5/TZ:MS-05
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel Aviv Sourasky Medical Center, Department of Neurology, Dr. Arnon Karni, PI.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tizanidine | Small molecule | 12 mg | Other |